We offer assistance to UNMC and UNO faculty, staff and students interested in starting companies with technology licensed from UNeMed. Entrepreneurs: read more…
UNeMed works with entrepreneurs, investors and consultants to form new companies around disclosed technologies. UNeMed nurtures these companies—identifying early investors, grant opportunities and potential leaders—while often taking an equity stake in the business.
Here’s a selection of active startups that got their start from University of Nebraska innovations. Most are still in early-stage product development and fundraising.
Burch Kealey, Ph.D., developed and licensed software to make EDGAR searches more efficient. Dr. Kealey, an accounting associate professor of at the University of Nebraska at Omaha, developed the program as a way to solve frustrations he encountered during a large research project.
Formed around an siRNA delivery system developed in the lab of Joe Vetro, Ph.D. The siRNA delivery system helps protect the siRNA from degradation and can be used to improve systemic administration of siRNA-based therapies. Actorius Pharmaceuticals is currently developing the siRNA delivery technology to treat various forms of cancer including breast cancer.
Originally named Camras Vision, the startup was founded on an intraocular pressure device developed by the late Carl Camras, M.D., a UNMC physician. His daughter, Lucinda, founded the company.
An early product of the Omaha startup scene and the Biomechanics Department at the University of Nebraska Omaha, Avert is building a non-invasive concussion detection system combining biomechanics, artificial intelligence and cloud computing. The result is highly accurate, low-cost device that can reliably determine when a person receives a concussion and when they recover.
Breezmed is a health informatics startup developing a new platform to ease workflow around prior authorizations. Breezmed streamlines the different documents insurance companies often require, making it easier for patients to get their prescriptions.
BromeCare Therapeutics is currently developing bromelain compounds for nutraceutical and pharmaceutical applications such as prevention and treatment of COVID-19.
Calidum Inc, was formed around an innovative approach for simultaneously treating and diagnosing some of the deadliest cancers. Janina Baranowska-Kortylewicz, Ph.D., a professor and radiochemist at UNMC, developed “theranostic” compounds tagged with a radioactive isotope that will help clinicians better diagnose, track and treat various cancers that include prostate, ovarian, and triple negative breast cancer. The compounds could also be used on two rare forms of brain tumors, neuroblastoma and glioblastoma.
Formed around a thermosensitive hydrogel formulation that can be used to deliver a variety of therapeutics. Developed by Dong Wang, Ph.D., the thermosensitive hydrogel formulation is a liquid at room temperature and a hydrogel once injected into the body, allowing for better control of drug releas. Ensign Pharmaceutical is initially focusing the development of the hydrogel formulation for the treatment of osteoarthritis.
A medical Device company built around the global expertise of Chandrakanth Are, M.D., and founded by the veteran entrepreneurs of St. Louis’ Exeteur group. GLS is building the portable laparoscope, a medical device concept that will bring laparoscopic surgery out the minimally invasive surgical suite and to billions of people currently underserved by surgical technology.
Intuitool Devices is the partnership between engineers at the University of Nebraska-Lincoln and the surgical expertise of the University of Nebraska Medical Center. Together, they created the next generation of ergonomic, semi-robotic laparoscopic tools: the Intuitool. Combining enhanced form, function and ergonomics, the Intuitool will make conventional tools obsolete by combining comfort, function and cost.
Late UNMC researcher Sam Sanderson, Ph.D., founded Prommune to develop his innovation, EP-67, a protein formulation that can serve as a platform to activate and enhance the natural immune system for a number of conditions. Prommune is currently focused on using EP-67 to deliver a more effective vaccine for the H1N1 virus in pigs. In the future, Prommune hopes to expand to other conditions and perhaps human use.
Co-founded by former Entrepreneur-In-Residence, Gary Madsen, Ph.D., ProTransit Nanotherapy is based on the work of former UNMC researcher Vinod Labshetwar, Ph.D., who is also a co-founder in the Omaha-based startup. ProTransit is developing a nanoparticle as a delivery vehicle for antioxidant enzymes to the deepest layers of the skin. The final product could be a topical application such as skin cream or sun lotion that better protects the skin against cancer, blemishes and wrinkles. There is also potential for additional applications that include treatment for some spinal cord injuries or certain types of brain damage.
Greg Gordon, M.D., a former interventional radiologist at UNMC and the Veteran’s Administration, is commercializing new tools that help reduce radiation exposure. The devices also reduce the stress and strain often experienced by interventional radiologists, improving their work flow, efficiency, career longevity and quality of life.
RespirAI is a medical device startup in the pulminary, cardiovascular, and long-term care spaces currently collaborating with Jennifer Yentes, PhD at UNO Biomechanics, Stephen Renard, MD at UNMC College of Medicine and their team to commercialize innovative respiratory monitoring devices.
ScanMed was created in the 1990s when UNMC faculty member Randy Jones, Ph.D., commercialized MRI coils he created. ScanMed later escaped the economic downturn by pivoting into a service company that repairs MRI scanning coils. More recently, ScanMed has enjoyed significant growth and now uses its repair service to bankroll some of the most innovative MRI coil designs in the world, including a novel prostate cancer screening coil that could dramatically improve a physician’s ability to make the earliest possible diagnosis.
Shabri specializes in rapid prototyping, batch manufacturing and product development. They design products in-house and use additive manufacturing methods to bring designs to life. They produce prosthetics and orthotics to help provide patients a better life, at an affordable cost. Shabri is currently collaborating with Jorge Zuniga, PhD, at UNO Biomechanics to commercialize novel 3D-printed prosthetics.
Formed to develop a novel glucocorticoid prodrug (ZSJ-0228) developed by UNMC researcher, Dong Wang, Ph.D. The novel glucocorticoid prodrug has improved efficacy and reduced toxicity compared to standard glucocorticoid treatments. Shannon Pharmaceuticals is developing ZSJ-0228 for the treatment of systemic lupus erythematosus and various kidney diseases.
Suh Hermsen Glasses is a leading innovator creating vision solutions for special needs and requirements that traditional eyeglass manufacturers can’t or won’t address. Suh Hermsen Glasses sells hundreds of ergonomic surgical loupe head straps monthly to dentists, ophthalmologists, surgeons, and jewelers, etc. Suh Hermsen Glasses is also developing modular glass frames with a pediatric focus.
Nebraska manufacturing startup Vireo Systems was established in Plattsmouth, Neb., about 20 miles south of Omaha. Vireo manufactures popular muscle-building health supplements that were developed at UNMC, Creatine Ethyl Ester and Creatine HCL. Vireo eventually outgrew its first facility, expanding into a larger space in 2012. More than 20 Nebraskans are employed at Vireo, which holds more than 40 manufacturing contracts.
Virtual Incision was born out of a collaboration between UNMC surgeon Dmitry Oleynikov and UNL robotics engineering professor Shane Farritor. Together, the cofounders are developing miniaturized surgical robots that could transform highly invasive major surgeries into minimally invasive procedures. Their surgical platform has also shown potential for remote surgical applications, and has undergone zero-gravity testing with NASA. In 2015 alone, Virtual Incision raised more than $11.2 million, and entered their first human trials in 2016.